Channel Therapeutics CORP S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Chromocell Therapeutics aims to raise up to $30 million through a committed equity financing facility with Tikkun Capital, as detailed in their S-1 filing.
Chromocell Therapeutics is seeking to raise capital through an IPO to further the development of its pain management therapeutics, primarily focusing on its lead compound CC8464 for Erythromelalgia.
Chromocell Therapeutics updates its S-1 filing, detailing IPO share offerings, potential resale by stockholders, and progress in developing its pain therapeutic, CC8464.
Chromocell Therapeutics updates its S-1/A filing for an initial public offering, aiming to list on the NYSE American under the symbol CHRO.
Chromocell Therapeutics aims to raise capital for pain therapeutics development through an initial public offering.
Chromocell Therapeutics amends a senior secured convertible note and files a resale prospectus for existing stockholders in connection with its IPO.